Biznextindia : Sputnik Vaccine, the COVID-19 vaccine by Russia’s Gamaleya National Center of Epidemiology and Microbiology have introduced a single dose version of the jab named as ‘Sputnik Light’. The vaccine has already been authorized to use in Russia.
The Russian Lab” has claimed that no serious adverse events were registered after vaccination with Sputnik Light. The single dose vaccine is compatible with standard vaccine storage and logistics requirements, while also being affordable with a price of less than $10.
“The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021. An efficacy level of almost 80% is higher than that of many two-dose vaccines. Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests” said a report released by Sputnik V.
“The Phase I/II of the Safety and Immunogenicity Study of the Sputnik Light vaccine has demonstrated that the vaccine can elicit the development of antigen specific IgG antibodies in 96.9% of individuals on the 28th day after vaccination. It elicits the development of virus neutralizing antibodies in 91.67% of individuals on the 28th day post immunization. Cellular immune response against the S Protein of SARS-CoV-2 develops in 100% of volunteers on the 10th day. The immunization of individuals with pre-existing immunity against SARS-CoV-2 with Sputnik Light can elicit the increase of the level of antigen specific IgG antibodies by more than 40x in 100% of subjects 10 days after immunization” it added.